Abstract:The 18-electron half-sandwich platinum group (Rh, Ru, Ir, and Os) metal anticancer complexes have been largely reported due to their easy tunable structure, high potency toward cancer cells, and specific mechanism of actions. However, the 16-electron (without the leaving group Cl-) half-sandwich complexes and their biological evaluation are rarely investigated. With an easy access to the required alpha-keto-beta-diimine ligands using m-CPBA as oxidant, we herein reported the synthesis and characterization of a panel of structurally related 16-electron piano-stool rhodium, iridium, and ruthenium complexes through the rearranged coordination reaction. These complexes have been well-established by NMR spectroscopy, mass spectrometry, single-crystal X-ray crystallography, and elemental analysis. Each of these complexes was stable and exhibited fluorescence in solution. Although no reaction with nucleobase (9-EtG and 9-MeA) was observed, the representative Rh5 showed affinity toward CT-DNA. These 16-electron complexes showed promising activity toward A549 and HeLa cancer cells with the values of IC50 in the range 7.1-32.3 mu M, which was comparable to or even better than cisplatin. In addition, the structure-activity relationships were observed that the change of the metal center from iridium(III) and ruthenium(II) to rhodium(III) could enhance the cytotoxicity of these unsaturated complexes. The investigation of mechanism of actions (MoAs) using flow cytometry displayed that the cytotoxicity of the complex Rh5 was associated with the perturbation of the cell cycle and the induction of cell apoptosis. Moreover, microscopic analysis by confocal microscopy suggested that the representative 16-electron complex Rh5 entered A549 cells via energy-dependent pathway and predominantly accumulated in lysosomes, thus resulting in the disruption of lysosomal integrity.

Lysosome-Targeted Chemotherapeutics: Half-Sandwich Ruthenium(II) Complexes That Are Selectively Toxic to Cancer Cells.

Half-sandwich ruthenium(ii) complexes containing N^N-chelated imino-pyridyl ligands that are selectively toxic to cancer cells.

Dual Functional Half-Sandwich Ru(II) Complexes: Lysosome-Targeting Probes and Anticancer Agents

Highly Potent Half- Sandwich Iridium and Ruthenium Complexes As Lysosome- Targeted Imaging and Anticancer Agents

16-Electron Half-Sandwich Rhodium(III), Iridium(III), and Ruthenium(II) Complexes As Lysosome-Targeted Anticancer Agents

Mitochondria-targeted half-sandwich rutheniumII diimine complexes: anticancer and antimetastasis via ROS-mediated signalling

In Vitro and in Vivo Antitumor Activity of Novel Half-Sandwich Ruthenium Complexes Containing Quinoline Derivative Ligands

Half-Sandwich Iridium and Ruthenium Complexes: Effective Tracking in Cells and Anticancer Studies

Fluorescent Half-Sandwich Phosphine-Sulfonate Iridium(iii) and Ruthenium(ii) Complexes As Potential Lysosome-Targeted Anticancer Agents

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Potent Half-Sandwich Ru(Ⅱ) N^N (Aryl-Bian) Complexes: Lysosome-mediated Apoptosis, in Vitro and in Vivo Anticancer Activities

A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Potent half-sandwich Ru(II) N^N (aryl-BIAN) complexes: Lysosome-mediated apoptosis, in vitro and in vivo anticancer activities

Lysosome-Targeted Potent Half-Sandwich Iridium(Iii) Alpha-Diimine Antitumor Complexes

Half‐sandwich Ruthenium (II) Complexes with Triphenylamine Modified Dipyridine Skeleton and Application in Biology/luminescence Imaging

Potent half-sandwich Ru(Ⅱ) N^N (aryl-BIAN) complexes: Lysosome-mediated apoptosis, in vitro and in vivo anticancer activities.

Organometallic ruthenium and iridium phosphorus complexes: Synthesis, cellular imaging, organelle targeting and anticancer applications: Organometallic Complexes Synthesis and Applications

Theranostic Lysosomal Targeting Anticancer and Antimetastatic Agents: Half-Sandwich Iridium(III) Rhodamine Complexes

Lysosomal-targeted anticancer half-sandwich iridium(III) complexes modified with lonidamine amide derivatives

Ruthenium Complex-Modified Carbon Nanodots For Lysosome-Targeted One- And Two-Photon Imaging And Photodynamic Therapy

Triphenylphosphine-Modified Iridium III , Rhodium III , and Ruthenium II Complexes to Achieve Enhanced Anticancer Selectivity by Targeting Mitochondria